With CancerDetect™, we bring next-generation cancer surveillance to the forefront—empowering proactive, personalized, and data-driven oncology care.

CancerDetect™ is our proprietary liquid biopsy platform designed to detect cancer recurrence at its earliest stages—well before it appears on traditional imaging. This advanced technology analyses unique genetic mutations found in a patient's surgically removed tumour, creating a highly personalized genetic panel for post-operative monitoring.

By targeting Minimal Residual Disease (MRD), CancerDetect™ offers a powerful, non-invasive method to identify early signs of relapse. It enables clinicians to anticipate recurrence months in advance, allowing for timely and tailored treatment interventions. This precision-driven approach enhances patient outcomes by enabling early therapeutic adjustments and optimizing chemotherapy strategies.